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Research
The effectiveness of characterizing changes in
gene expression in response to chemical expo-
sure, therapeutic or toxic, or caused by changes
in physiological status of tissues or organs (dis-
ease, development, etc.), has grown exponen-
tially in the past few years because of the
availability of cost-effective microarray technol-
ogy. Microarrays allow the quantitative analysis
of thousands of gene expression changes simul-
taneously in a single experiment, orders of mag-
nitude more than the number that could be
evaluated using older technologies for quantita-
tive gene expression [i.e., Northern blot, RNase
protection, quantitative real-time polymerase
chain reaction (QRT–PCR)]. This approach
has led to the discovery of multiple genes puta-
tively involved in particular biochemical
processes. Once a subset of relevant genes has
been identiﬁed, the next step usually focuses
on the response of that subset, for example, to
conﬁrm or reﬁne potential therapeutic or toxic
targets. This step has been performed largely
using traditional methods, namely, QRT–PCR
or Northern blot analysis. However, these
methods are time- and sample-consuming
because of their one-gene-at-a-time approach.
What is needed is an intermediate technology
to evaluate changes in the expression level of
10–100 genes (multiplexed), with high speci-
ﬁcity, sensitivity, and reproducibility.
In previous studies using high-density
oligonucleotide arrays, we have shown that
exposure to various estrogen receptor (ER)
agonists induced a characteristic gene expres-
sion profile in the developing reproductive
system of the female rat (Naciff et al. 2002,
2003). Among these genes, there is a subset
whose changes in expression are specific
for estrogen exposure. Using this subset of
genes (molecular fingerprint) rather than a
single biomarker, we have developed a high-
throughput gene expression assay based on the
Luminex xMAP system (Luminex Corp.,
Austin, TX). The Luminex system is a multi-
analyte bioassay detection system capable of
performing up to 100 assays simultaneously in
a single microtiter plate well. This system uses
polystyrene microspheres internally dyed with
red and infrared ﬂuorophores that can be indi-
vidually identified. The fluorescent micro-
spheres can be coated with a reagent speciﬁc
to a particular bioassay, allowing the capture
and detection of speciﬁc analytes from a sam-
ple. This assay has been used to quantify pro-
teins, genotype patients, and test viral loads in
a multiplex platform (Brodsky and Silver
2002; Dunbar et al. 2003; Fulton et al. 1997;
Gordon and McDade 1997; Morgan et al.
2004; Oliver et al. 1998; Smith et al. 1998;
Vignali 2000). To date, there are many kits
available to measure different proteins (Earley
et al. 2002; Luminex 2005) in different sam-
ples based on the Luminex microspheres.
However, there is only a single reference in
the literature describing the use of this
approach to quantify gene expression at the
level of RNA transcripts (Yang et al. 2001).
These authors have shown the ability to detect
the expression level of up to 20 genes simulta-
neously with a lower detection limit of
100 amol. This detection limit allows the
evaluation of only the moderately to highly
expressed genes, a limitation to its broader
applicability. We report here significant
improvements to the assay that increases the
sensitivity by two orders of magnitude, down
to a single attomole of labeled target in a com-
plex target mixture (for comparison, the
detection limit of the Affymetrix microarray
chip is about 15 amol per transcript). The
assay we have developed is suitable for detec-
tion of up to 100 different transcripts with
high throughput of hundreds to thousands of
samples per day, with high accuracy, speed,
sensitivity, and flexibility (add or subtract
speciﬁc transcripts). It is particularly valuable
for applications requiring the detection of a
moderate number of transcripts in thousands
of samples.
Our necessity for a high-speed multiplex
assay has been driven by an imminent
U.S. Environmental Protection Agency (EPA)
requirement to determine the potential for the
chemicals it regulates to interact with estro-
gen, androgen, or thyroid hormone system
(U.S. EPA 2005). We believe that gene
expression analysis has the greatest potential to
evaluate these interactions in a sensitive and
speciﬁc manner and is most amenable to the
development of in vitro alternatives. We have
used microarray analysis to determine changes
in gene expression (to identify a “molecular
ﬁngerprint”) induced by estrogens, including
the potent ER agonist, 17α-ethynyl estradiol
(EE), in the female reproductive system of the
rat. Previous studies in this laboratory have
shown that transplacental exposure to various
ER agonists (genistein, bisphenol A, and EE),
or direct exposure (in prepubertal female rats)
elicited a specific profile of gene expression
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Recently gene expression studies have been multiplied at an accelerated rate by the use of high-
density microarrays. By assaying thousands of transcripts at a time, microarrays have led to the dis-
covery of dozens of genes involved in particular biochemical processes, for example, the response of
a tissue/organ to a given chemical with therapeutic or toxic properties. The next step in these stud-
ies is to focus on the response of a subset of relevant genes to verify or reﬁne potential therapeutic
or toxic properties. We have developed a sensitive, high-throughput gene expression assay for this
purpose. In this assay, based on the Luminex xMAP system, carefully selected oligonucleotides were
covalently linked to ﬂuorescently coded microspheres that are hybridized to biotinylated cRNA fol-
lowed by ampliﬁcation of the signal, which results in a rapid, sensitive, multiplexed assay platform.
Using this system, we have developed an RNA expression proﬁling assay speciﬁc for 17 estrogen-
responsive transcripts and three controls. This assay can evaluate up to 100 distinct analytes simul-
taneously in a single sample, in a 96-well plate format. This system has improved sensitivity versus
existing microsphere-based assays and has sensitivity and precision comparable with or better than
microarray technology. We have achieved detection levels down to 1 amol, detecting rare messages in
complex cRNA samples, using as little as 2.5 µg starting cRNA. This assay offers increased through-
put with decreased costs compared with existing microarray technologies, with the trade-off being in
the total number of transcripts that can be analyzed. Key words: endocrine disruptor, estrogen-
regulated gene expression, ﬂuorescently coded microspheres, high-throughput gene expression assay,
multiplex. Environ Health Perspect 113:1164–1171 (2005). doi:10.1289/ehp.7843 available via
http://dx.doi.org/ [Online 12 May 2005]changes in response to these chemicals (Naciff
et al. 2002, 2003). From the set of affected
genes, we have chosen a subset for which
expression is strongly inﬂuenced by estrogen
exposure that was used as a test case for evalu-
ating the performance of the microsphere-
based assay.
Materials and Methods
Animals, treatments, and target preparation.
Total RNA was isolated and puriﬁed according
to the method previously reported by this labo-
ratory (Naciff et al. 2003). Brieﬂy, 15-day-old
Sprague-Dawley female rats (Charles River,
Raleigh, NC) were obtained and housed for
5 days before treatment. The experimental pro-
tocol was carried out according to Procter &
Gamble’s approved protocols for animal care,
and animals were maintained in accordance
with the National Institutes of Health Guide
for the Care and Use of Laboratory Animals
(Institute of Laboratory Animal Resources
1996). On day 20 the rats were treated with
either vehicle (peanut oil) or 0.1, 1.0, or
10.0 µg/kg EE each day for 4 consecutive days.
This dose regimen was selected to elicit a
graded (dose-dependent) uterotrophic
response in the immature rat as indicated in
Naciff et al. (2003). On day 24 the rats were
sacriﬁced. The reproductive tissues (uteri with
ovaries attached) were excised, trimmed of fat
and connective tissue, and stored in RNAlater
(Ambion, Inc., Austin, TX) at 4°C. We chose
to evaluate the uterus and ovaries as a pool
because they are two of the tissues most sensi-
tive to estrogenic regulation. Although we real-
ize that this may result in loss of information
about gene expression in one or the other
organ, we believe that from a screening perspec-
tive we have taken the best approach because
these organs contain considerable variation in
the expression levels of the two ER isoforms,
ER-α and ER-β, and consequently have the
potential to represent gene expression changes
induced by activation of any of the isoforms of
the ER in the target tissues. RNA was isolated
using TriReagent (Molecular Research Center,
Inc., Cincinnati, OH). Total RNA was further
purified using the RNeasy Kit (Qiagen Inc.,
Valencia, CA) and stored at –80°C. Ten
micrograms of RNA, from five independent
samples (biologic replicates), was then con-
verted into double-strand cDNA. The Enzo
Bioarray RNA Transcription Kit (Affymetrix
Inc., Santa Clara, CA) was then used to gener-
ate 50–75 µg of biotin-labeled cRNA. The
cRNA was fragmented and hybridized to
Affymetrix rat 34A chips. Unused fragmented
cRNA was stored at –20°C until use for these
experiments. The batch of cRNA was used in
the many steps of optimizing the assay until
none was left. The data shown here in the ﬁnal
assay are from a new batch of cRNA generated
from the original stock of total RNA, which
was used to generate the cRNA evaluated by
microarray analysis. To fully assess the overall
quality of each sample, the newly labeled
cRNA samples were hybridized to the
Affymetrix GeneChip Test 3 Array as previ-
ously described (Naciff et al. 2003).
Oligonucleotides. To verify the data from
the microarray experiments, we chose to use a
single oligonucleotide to conﬁrm the data from
16–20 oligos that are tiled for each feature on
the U34A rat chips (for a full description of the
rat U34A array content, see Affymetrix 2005).
Brieﬂy, in the rat genome U34A high-density
oligonucleotide microarray, each gene or
expressed sequence tag (EST) is represented by
16–20 pairs of 25-mer oligonucleotides that
span the coding region. Each probe pair con-
sists of a perfect match sequence that is com-
plementary to the cRNA target and a sequence
that is mismatched by a single base change at
the middle of the nucleotide, a region critical
for target hybridization. The mismatched
oligonucleotide serves as a control for non-
specific hybridization. We hypothesized that
one probe could be used for the evaluation of
the corresponding transcript. To identify the
best possible oligonucleotide (probe), we
designed an algorithm that allowed us to select
the best-performing probe (oligonucleotide)
from the entire probe set. This algorithm eval-
uates different parameters that best predict the
results that were obtained from all probes in
the feature. Another option was to select the
best two or even three probes. Thus, the
second- and third-best-performing probes, for
each transcript selected, were identiﬁed using
the different parameters evaluated by the algo-
rithm. To test the validity of our approach,
two oligonucleotides were identiﬁed as being
the best-performing probes to evaluate the
mRNA level for the rat glyceraldehyde
3-phosphate dehydrogenase (GAPDH).
Additionally, because Affymetrix chips employ
a set of perfect match–mismatch pair of
oligonucleotides tiled onto the microarray to
better evaluate the speciﬁc signal of any given
mRNA, relative abundance, we decided to
apply this strategy to the microsphere assay. To
test this approach, a perfect match and a mis-
match probe for 11β-hydroxysteroid dehydro-
genase (Hsd11b2) were identiﬁed and used for
the evaluation of the mRNA level of Hsd11b2
in the different samples. Empirical determina-
tion of the value of using the mismatch probe,
paired with the data obtained from the perfect
match probe, indicated that the speciﬁcity of
the signal was not improved by its use (data
not shown). The signal values from the perfect
match probe are highly specific and are the
only ones reported. The different probes
selected are indicated in Table 1.
Coupling of oligonucleotides to micro-
spheres. Transcript-specific oligonucleotides,
corresponding to the complementary sequence
of the desired mRNA (Table 1), were cova-
lently coupled to ﬂuorescently distinct sets of
carboxylate-modified polystyrene xMAP
microspheres using water-soluble carbo-
diimide. All oligonucleotides were purchased
from Integrated DNA Technologies Inc.
(Coralville, IA) and were synthesized with a
5´-amino linker and a C12 spacer. These oligos
were coupled covalently to 20 ﬂuorescently dis-
tinct sets of carboxylated microspheres as previ-
ously detailed (Fulton et al. 1997) at a ratio of
1 nmol of modified oligo to 1 × 107 micro-
spheres. The 20 sets of carboxylated polystyrene
microspheres (5.6 µm in diameter) of differing
ﬂuorescence addresses (determined by its spec-
tral signature determined by its red/infrared ﬂu-
orophore ratio) were ordered from Luminex
Corp. Speciﬁcally, 1 × 107 microspheres were
pelleted in a microcentrifuge (12,000 × g) for
2 min, and the supernatant was carefully
removed. The microspheres were resuspended
in 50 µL of buffer containing 0.1 M MES
[2-(N-morpholino)ethanesulfonic acid; Sigma-
Aldrich Co., St. Louis, MO] at pH 4.5. The
amino-substituted oligonucleotides were dis-
solved in double-distilled H2O to 1 mM and
stored at –80oC. For the coupling reaction,
1 nmol of the appropriate oligonucleotide was
added to the desired microsphere set. The reac-
tion was initiated by adding 2.5 µL of freshly
prepared 10 mg/mL 1-ethyl-3-(3-dimethyl-
aminopropyl) carbodiimide hydrochloride
(EDC; Pierce, Rockford, IL), followed by
incubation of the mixture for 30 min at room
temperature, in the dark. After the initial
30 min incubation, a second 2.5 µL of freshly
prepared EDC solution (10 mg/mL) was added
to the reaction and incubated for an additional
30 min. The coupling reaction was terminated
by adding 1 mL of 0.02% Tween 20 (poly-
oxyethylenesorbitan monolaurate; Sigma-
Aldrich Co.) to the microsphere suspension,
vortexed, and then centrifuged (12,000 × g) for
4 min; the supernatant containing free oligonu-
cleotides and unreacted EDC was removed. To
ensure that all the uncoupled oligonucleotides
were removed, the microspheres were washed
with 1 mL of 0.1% SDS (Sigma-Aldrich Co.).
The oligonucleotide-conjugated microspheres
were resuspended in 1 mL of TE buffer
(10 mM Tris, 1 mM EDTA, pH 8.0; Sigma-
Aldrich Co.), counted on a hemacytometer,
adjusted to a concentration of 1 × 107 micro-
spheres/mL, and stored in TE at 4oC, protected
from the light. Complementary sense-strand
oligos were ordered with a 5´ biotin modiﬁca-
tion to be used for titration curves for each set
of the coupled microspheres.
Hybridization. To optimize the system,
initial experiments used biotinylated comple-
mentary sense-strand probes to develop a titra-
tion curve to examine the sensitivity of the
assay. In this assay five genes (analytes) were
chosen to evaluate the sensitivity of this system.
A bead-based high-throughput gene expression assay
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were combined in a well of a 96-well plate
containing 1× TMAC [3 M tetramethyl-
ammonium chloride, 0.1% SDS; 50 mM
Tris–HCl, pH 8.0; and 4 mM EDTA,
pH 8.0; Sigma-Aldrich Co.] in a total volume
of 50 µL. Biotinylated complementary
oligonucleotide (4 µL) at varying concentra-
tions (one-half log serial dilutions for 100 fmol
to 100 amol) diluted in TE (10 mM Tris and
1 mM EDTA, pH 8.0) was added and mixed.
Samples were heated at 95°C for 2 min. The
mixture was transferred to a 48°C shaking heat
block (Eppendorf Thermomixer; Eppendorf
North America, Inc., New York, NY) for 1 hr.
The samples were spun at 2,500 × g, and the
supernatant was removed by inverting the plate
over the waste container and tapping one time
on a table covered with absorbent paper.
Samples were washed once with 1× TMAC
and resuspended with 65 µL streptavidin–
phycoerythrin (SAPE; Molecular Probes,
Eugene, OR) stain (5 µg/mL SAPE in 1×
TMAC) for 15 min at room temperature. The
samples were then analyzed on a Luminex 100
instrument (Luminex Corp.).
For the amplification of the signal (see
“Results”), the following steps were added to
the protocol. After the washes after the SAPE
stain, the microspheres were incubated for
60 min with biotinylated anti-streptavidin
antibody (Vector Laboratories, Burlingame,
CA) with goat IgG (Sigma-Aldrich Co.) to
block nonspeciﬁc binding. The microspheres
were spun, the supernatant was removed, and
the microspheres were then stained again
(Table 4) with 50 µL SAPE for 10 min. The
microspheres were then washed a final time
with PBS–1% BSA and analyzed.
Through empiric determination, the opti-
mized protocol (Table 4) has incorporated the
following changes: 1× TMAC was replaced
with 0.5× TMAC, the two SAPE incubations
and the anti-streptavidin incubation steps were
performed with PBS–1% BSA as the buffer;
and the bead concentration was reduced
10-fold. Because the ﬂow cytometric analysis is
done at a preset photomultiplier (PMT) set-
ting, there is the possibility that when a given
transcript is relatively abundant (high copy
number), the signal values could reach satura-
tion, whereas the signal values derived from the
hybridization of uncommon transcripts (low
copy number) to their specific microspheres
could be relatively low. To avoid this potential
problem, and taking advantage of the instru-
ment used in our studies [Luminex 100 system
from Luminex Corp. or Bio-Plex Suspension
Array System from Bio-Rad Laboratories, Inc.
(Hercules, CA)], we analyzed the ﬂuorescence
signal values at two PMT settings (low and
high) to expand the dynamic range of the assay
without losing sensitivity.
Instrumentation. Samples run at Radix
BioSolutions were read on a Luminex 100
(SP1 software, version 1.7.69; Luminex
Corp.). Samples run at Procter & Gamble’s
Miami Valley laboratories were read on the
Bio-Rad Bio-Plex (Bio-Rad’s version of the
identical Luminex 100 ﬂow cytometer) using
the Bio-Plex Manager software, version 2.0.
Each system integrates lasers, optics, ﬂuidics,
electronics, and signal processing to identify
each set of fluorescent-coded microspheres
from each set and to measure the total ﬂuores-
cence at the surface of each microsphere to
quantify the amount of reporter bound to it.
The median fluorescence intensity (MFI),
derived from reading at least 100 microspheres
from each set, was used as a representation of
the whole population of microspheres of each
set in any given sample. The MFI from five
independent samples (biological replicas),
from control or from each EE-treated animal,
were determined and used to determine the
average fold change on the expression of the
transcript of interest.
QRT–PCR. To verify the relative change
in gene expression identified by both the
microspheres and the oligonucleotide
microarrays, we used a real-time (kinetic)
QRT–PCR approach as previously described
by this laboratory (Naciff et al. 2002, 2003).
The primers used for the QRT-PCR have
also been published (Naciff et al. 2003).
Results
Design of the transcript quantiﬁcation assay.
Our goal was to quantify the amount of spe-
ciﬁc transcripts present in a complex mixture
of cRNA with a sensitivity and speciﬁcity com-
parable with at least those obtained from the
microarray analysis. To this end we chose
oligonucleotides with unique sequences of
25 bases in length, based upon the best-
performing probes tiled on the Affymetrix rat
genome U34A high-density oligonucleotide
microarray. Effective oligonucleotide probes
for each transcript were selected based on the
data from 44 chip hybridizations (Naciff et al.
2003), using a statistical algorithm (Juhlin KD,
Carr GJ, Jump ML, Richardson BD, Torontali
SM, unpublished data), and the analyzed data.
The expression of 17 of the 20 target tran-
scripts evaluated in this article is regulated by
estrogens in a dose-dependent manner. We
also included two internal control transcripts
(vascular α-actin and cyclophilin B) that are
also expressed in the uterus/ovaries of the
immature rat but whose expression is not regu-
lated by estrogens in these organs. An oligo-
nucleotide specific for a bacteriophage M13
gene was also included as an external control.
Naciff et al.
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Table 1. Genes selected for the bead-based high-throughput gene expression assay (20-plex format).
Accession no. Gene name Gene symbol Probe sequence
AB006007 steroidogenic acute regulatory protein Star 5´-ACGTGGCTGCTCAGTATTGACCTCA-3´
AF022147 uterus-ovary speciﬁc putative transmembrane protein Cuzd1 5´-CGTCATGCTCGTATCACAGCCTCAG-3´
or CUB and zona pellucida-like domains 1
K03249 peroxisomal enoyl-CoA-hydrotase-3-hydroxyacyl-CoA Ehhadh 5´-TGGATCTGTAACACATTGAGTTCAA-3´
L00191 ﬁbronectin 1 Fn1 5´-TGGCCACACCTACAACCAGTATACA-3´
L11007 cyclin-dependent kinase 4 Cdk4 5´-TGGAGTGTTGGCTGTATCTTCGCAG-3´
L26292 FSH-regulated protein or Kruppel-like factor 4 Klf4 5´-TTTGTCTTCCGATCTACATTTATGA-3´
M14656 osteopontin or secreted phosphoprotein 1 Spp1 5´-AGAGAGTTCATCTTCTGAGGTCAAT-3´
M29866 complement component C3 C3 5´-GTCAAGGTCTACTCCTACTACAATC-3´
M31837 insulin-like growth factor-binding protein 3 Igfbp3 5´-TACAGAGCTTTCCTTGAGAGCACAA-3´
M57664 cretine kinase-B Ckb 5´-GTTTTTGATGTCTCCAACGCTGACC-3´
M86389 heat shock protein 27 Hspb1 5´-ATGAGTGGTCTCAGTGGTTCAGCTC-3´
X82396 cathepsin B Ctsb 5´-GCTGCACCTTGAAGCTAGTCACTTC-3´
Y08358 eotaxin or small inducible cytokine subfamily A11 Scya11 5´-GAAATAGGGTCTCACTGTATCACCC-3´
X06801 vascular alpha-actin VaACTIN 5´-TACTGCTGAGCGTGAGATCGTCCGT-3´
S64044 progesterone receptor Pgr 5´-TTTGCACCTGATCTAATCCTGAATG-3´
V00604 bacteriophage M13 M13 5´-AAGCAACCATAGTACGCGCCCTGTA-3´
K00994 intestinal calcium-binding protein or calbindin 3 Calb3 5´-CGACACCACCTACTGATTGAATCCT-3´
M21208 cytochrome P450, family 17, subfamily a, polypeptide 1 Cyp17a1 5´-CTCAACACCCACAGTACAATCTTAG-3´
U22424 11-beta-hydroxylsteroid dehydrogenase type 2 Hsd11b2 5´-TCATGAGACCATGTATACCCTACCA-3´
AF071225 cyclophilin B or peptidylprolyl isomerase B  Ppib 5´-AGCAAGTTCCATCGTGTCATCAAGG-3´
Gene annotations are from GenBank (http://www.ncbi.nih.gov/GenBank) with the exception of VaACTIN and M13.A bead-based high-throughput gene expression assay
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The sequences of the oligonucleotides are
shown in Table 1.
Sensitivity and speciﬁcity of hybridization
of the selected oligonucleotides coupled to
ﬂuorescent microspheres. Each of the 20 oligo-
nucleotides, derived from the 19 Rattus
norvegicus genes and a control bacterio-
phage M13, was coupled to xMAP micro-
spheres with a unique fluorescence emission
wavelength. Each microsphere set was evalu-
ated individually for specificity and sensitiv-
ity, after which the different microsphere sets
were combined for multiplexed assays.
To determine the speciﬁcity and sensitiv-
ity of the assays and to optimize the system,
initial hybridization experiments used a titra-
tion of biotinylated complementary sense-
strand probes. Five speciﬁc microspheres sets
were used to evaluate the sensitivity of this
system. A complex mixture of different con-
centrations of synthetic complements, which
included the antisense oligonucleotides spe-
cific for M13, Calb3, Cyp171a, Pp1b, and
Hsd11b2 (sequences are given in Table 1),
was mixed with oligonucleotides specific to
GAPDH-5´ and GAPDH-3´ mRNA region
(5´-CGTCAAGATCAAATGGGGTGAT
GCT-3 and 5-ATCCTGGGCTACACT
GAGGACCAGG-3´, respectively), and a
single-base mismatch for Hsd11b2 (mutation
on the central region, 5´-TCATGAGACC
ATcTATACCCTACC-3´). Oligonucleotide-
coupled microspheres were combined with
different concentrations of biotinylated com-
plementary oligonucleotides and allowed to
hybridize at 48°C. The signal of each analyte
bound to each type of microsphere present in
the reaction was determined using SAPE as a
reporter fluorescent tag. A negative control
consisted of all assay reactants except for the
biotinylated complementary oligonucleotides.
The median fluorescent intensity of at least
100 microspheres of each set was calculated by
the software. The intensity of the hybridiza-
tion signals is linearly related to the amount of
analyte being evaluated, from 0 to 36.1 fmol,
for each oligonucleotide–microsphere set
(Figure 1). The assay was no longer linear at
higher concentrations of analyte (100 fmol).
The specificity of the hybridization is not
compromised as the number of analytes
increases.
Evaluation of the sensitivity and speci-
ficity of the assay in experimental samples.
The transcripts to be analyzed (analytes or
targets) were biotin-labeled cRNAs, prepared
from the uterus/ovaries of prepubertal rats
exposed to vehicle control or various doses of
EE for 4 days (0.1, 1, or 10 µg EE/kg/day,
low, mid, or high doses, respectively, n = 5 for
each dose group), collected from a previous
study (Naciff et al. 2003). Each sample from
every dose group was analyzed independently
and used as a biological replicate.
Initial sensitivity results of the micros-
phere-based assay were not within the range
needed for the detection of all transcripts. The
hybridization signal from one transcript,
intestinal calcium-binding protein (Calb3), is
shown in Figure 2. Although the assay clearly
allows for the determination of the changes
induced in Calb3 by EE exposure (control vs.
low, mid, or high doses; C, L, M, and H
respectively), the corresponding signal values
were near the lower end of the sensitivity. The
signal intensities obtained were similar to those
obtained by Yang et al. (2001). The fluores-
cence intensity (signal value) corresponding to
the transcript levels of Calb3 in the control
sample (vehicle treated) was extremely low
(44 units with 5 µg cRNA and 68 units with
10 µg cRNA). Calb3 is known to be a
gene transcript that shows a moderately high
expression in control samples and is stimulated
to high expression levels with high doses of EE
as shown by Affymetrix GeneChip data
(4,700 units in control to 49,400 units in
high-dose group with a chip scaling factor of
1,500). Although the ﬂuorescence signal had
high speciﬁcity (Figure 1) and it was well above
the background level (the ﬂuorescence of the
microspheres not exposed to cRNA), in the
context of a very complex cRNA background
the small signal intensity left little room for the
detection of gene transcripts that were
expressed less abundantly than Calb3.
Signal ampliﬁcation using biotin-labeled
anti-streptavidin antibody. To amplify the
signal from our microspheres assay, we used a
biotin-labeled anti-streptavidin antibody
ampliﬁcation system. The signal intensity was
ampliﬁed, after hybridizing the microspheres
with their targets (cRNA), by a second stain-
ing with a biotin-labeled anti-streptavidin
antibody followed by a second streptavidin-
R–phycoerythrin staining. Incorporating the
antibody ampliﬁcation step into the assay, as
described in “Materials and Methods,” led to
an average increase in signal intensity of
approximately 5- to 10-fold (Figure 2). The
fluorescent signal corresponding to the tran-
script levels of Calb3 in control samples
increased approximately 4-fold from 68 units
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Figure 1. Sensitivity and speciﬁcity of the assay. To determine the speciﬁcity and sensitivity of the assays,
a series of multiplexed hybridization reactions were performed. Four different biotinylated complementary
oligonucleotides (Calb3, M13, Cyp17a1, and Ppib) were hybridized at different concentrations (0, 0.1, 0.316,
1, 3.16, 10, 31.6, 100 fmol) to eight different sequence-specific microsphere sets. The data demonstrate
undetectable cross-hybridization. Calb3, intestinal calcium-binding protein, or calbindin 3; Cyp17a1,
17α-hydroxylase cytochrome P450; Ppib, cyclophylin B or peptidylprolyl isomerase B.
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Figure 2. Comparison of the quantiﬁcation of Calb3
expression with and without signal amplification.
Biotinylated cRNA samples from control (C) vehi-
cle-treated or EE-exposed tissues (0.1, 1.0, or
10.0 µg/kg/day; L, M, and H, respectively) were
hybridized to microspheres coupled to the speciﬁc
probe for Calb3, and the ﬂuorescent intensity of at
least 100 microspheres was determined (nonampli-
fied). To increase the signal value, two equivalent
sets of samples were hybridized to the specific
Calb3 microspheres, washed, and then hybridiza-
tion signal was ampliﬁed as indicated in ”Materials
and Methods.” A clear dose response to EE expo-
sure can be determined in both cases; however,
the amplification step increases the sensitivity of
the assay.Naciff et al.
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to 234 units using 10 µg cRNA, but the
ﬂuorescent signal of the sample derived from
tissues exposed to EE in the high-dose group
(10 µg/kg/day) increased from 980 to
10,632 units by using the ampliﬁcation step.
To better understand the magnitude of
increased sensitivity from the amplification
step, we measured the increase in signal
obtained with a titration curve of comple-
mentary biotinylated oligonucleotide. The
saturation concentration is relative to the
maximum signal value of the detector in the
flow cytometer. In Figure 3A, the titration
curve of a biotinylated complementary
oligonucleotide for Calb3 is shown for the
comparison of the nonamplified and ampli-
fied signal. The assay sensitivity increased
approximately 10-fold in the ampliﬁed assay
compared with the nonampliﬁed assay.
Additional refinements to the assay,
including changes in the hybridization buffer,
the incubation time, and instrument PMT set-
tings, have led to an additional 10-fold increase
in sensitivity. Fluorescent signals are now at
least 8- to 20-fold above background, which
makes data calculations far more reliable
(Figure 3B), for relatively low abundance as
well as abundant transcripts.
The signal amplification steps do not
change the linearity of the relationship between
the amount of target quantiﬁed and the mag-
nitude of the signal regardless of the complex-
ity of the sample or the level of multiplexing
(Figure 4A). The signal amplification step
allows the simultaneous quantiﬁcation of mul-
tiple analytes in the linear range from 1 up to
1,000 amol. In addition Figure 4B demon-
strates that a titration of cRNA from rat uterus/
ovaries (1, 2.5, 5, or 10 µg total) has no effect
on the sensitivity of the assay for the control
biotinylated complementary oligonucleotide
for M13. As can be seen in Figure 4B, even in
the context of the whole population of labeled
uterine/ovarian cRNA of the rat, the ampliﬁca-
tion of the signal does not modify the speci-
ﬁcity or the sensitivity of the assay
Gene expression changes induced by EE in
the uterus/ovaries of the prepubertal rat:
microarray versus microsphere-based approach.
To evaluate the overall performance of the mul-
tiplex assay, the expression levels of the
20 selected genes were evaluated under the
optimized conditions. After hybridization and
ampliﬁcation of the signal, the expression levels
of the 20 genes were measured simultaneously.
Replicate measurements from ﬁve independent
biological samples (biological replicas) from
each dose group (0, 0.1, 1, and 10 µg
EE/kg/day; control, low, mid, and high dose,
respectively) were made. The reproducibility of
the assay is represented in Figure 5 with the
determination of the expression levels of Calb3,
an up-regulated gene, and Cyp17a1, a down-
regulated gene, in independent samples. The
comparison of the signal values (arbitrary ﬂuo-
rescent units) obtained from the microarray
analysis (Affymetrix) versus the ones obtained
from the optimized xMAP assay for four repre-
sentative transcripts is shown in Table 2. It is
clear that there is a high concordance on the
hybridization signal values between the two
methods, which results in a one-to-one corre-
spondence in the gene expression changes
determined by microarray analysis and by the
xMAP assay. In both cases, there is a clear dose
response for genes that are up-regulated (C3,
Scya11, and Ehhadh) or down-regulated (Star)
by EE exposure. Further, the transcripts that
are found at relatively low copy number, up-
regulated genes in control samples or down-
regulated in high-dose–treated samples, or at a
high-copy-number, down-regulated genes in
controls or up-regulated genes in EE-treated
samples, can be quantiﬁed unambiguously.
The results from the evaluation of the
17 target transcripts representing the product of
genes whose transcription is regulated by estro-
gens, as well as two genes not regulated by
estrogens (internal controls: vascular α-actin
and cyclophilin B), from the uterus/ovaries of
the immature rats exposed to 10 µg EE/kg/day
(high dose) are shown in Table 3. The
Affymetrix microarray data for the indicated
genes, and many others, have already been pub-
lished (Naciff et al. 2003). The relative expres-
sion level was determined by calculating the
ratio of high-dose EE-treated to control-treated
samples. Some experiments (run 1, multiple
quantiﬁcations in independent samples) were
performed at Radix Biosolutions, where the
hybridization signal was quantified using a
Luminex 100 SP1 software, version 1.7.69.
Replicate experiments (run 2) of the same sam-
ples were performed at Procter & Gamble,
where the hybridization signal was quantiﬁed
on a Bio-Rad Bio-Plex (Bio-Rad’s version of
the Luminex 100) using the Bio-Plex Manager
software, version 2.0 . For most of the analytes,
the fluorescent signals were highly repro-
ducible, particularly when the analyte repre-
sented low or moderately abundant transcripts
(Table 3). However, there were some discrep-
ancies with the quantitation of transcripts with
high copy number, such as C3 (complement
component 3). The samples read on the
Bio-Plex instrument were taken at the high
PMT setting to enhance the instrument’s over-
all sensitivity; however, this setting causes the
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Figure 3. Example of the optimization of the hybridization assay for the quantification of Calb3. (A)
Antisense oligonucleotide for Calb3, at various concentrations (1, 10, 100, 1000, 10,000, and 100,000
amol/sample), was hybridized to the speciﬁc Calb3 microspheres coupled to the speciﬁc probe for Calb3,
and the mean ﬂuorescence intensity of at least 100 microspheres was determined (standard). To increase
the signal value, equivalent samples of antisense oligonucleotide for Calb3 were hybridized to the speciﬁc
Calb3 microspheres and washed, and then hybridization signal was amplified as indicated in methods
(amplified or base). (B) The optimization of the hybridization conditions, as indicated in “Materials and
Methods,” resulted in a greater increase in sensitivity of the assay (optimized). 
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Figure 4. Specificity and dynamic range of detection with amplification. Signal amplification does not
change the linearity of the relationship between the amount of target quantiﬁed and the magnitude of the
signal, even when the analyte is found within a complex mixture of cRNA potential targets. (A) Antisense
oligonucleotide for Calb3, Cyp17a1, Ppib, and M13 at various concentrations (1, 10, 100, 1000, 10,000, and
100,000 amol/sample) were mixed and hybridized to the speciﬁc Calb3-, Cyp17a1-, Ppib-, and M13-speciﬁc
microspheres in a four-plex format, and the mean ﬂuorescence intensity of at least 100 microspheres was
determined after the hybridization signal was amplified as indicated in methods. (B) The indicated
amounts of M13 antisense oligonucleotide were mixed with fragmentation buffer or with various amounts
of a highly complex cRNA sample, and then hybridized with M13-speciﬁc microspheres. PMT to reach signal saturation more readily.
Thus, for highly expressed genes such as C3,
signal saturation on the Bio-Plex instrument
resulted in discordant data between the repli-
cate experiments. Changing the PMT gain
setting of the Bio-Plex (or the Luminex) instru-
ment and rereading the same samples allowed
the determination of analytes present in the
samples at relatively high copy numbers and
did not modify the quantitation of the other
analytes (Table 3). A second reading of the
same samples shows only a 10% (± 3%) loss of
the signal intensity by photobleaching of the
reporter (data not shown). Thus, reading the
hybridization signal of the same test samples at
two PMT settings (low and then high) results
in the expansion of the dynamic range of the
assay without losing sensitivity.
Discussion
We have developed a high-throughput gene
expression profiling assay using fluorescent
labeled microspheres coupled with gene-
speciﬁc oligonucleotides to evaluate the effects
of estrogen exposure in the prepubertal rat.
Substantial improvements on existing bead-
based assays have been made that result in an
assay that is highly correlated in relative gene
expression changes determined by established
microarray technologies. These improvements
include an anti-streptavidin amplification
method that produces a 10-fold increase as
well as changes to the hybridization buffer,
assay kinetics, and hybridization temperature.
Using these improvements, a detection limit of
1 amol of complementary RNA has been
achieved, allowing the analysis of rare messages
in complex cRNA samples using as little as
2.5 µg starting material. This assay offers
increased throughput with decreased costs
compared with existing microarray technolo-
gies, allowing the determination of gene
expression changes specifically, rapidly, and
with high sensitivity and resolution. This sys-
tem is a rapid multiplexed assay platform that
quantiﬁes up to 100 distinct analytes simulta-
neously in a single sample in a 96-well plate
format. The microsphere-based assay format
provides the ﬂexibility to rapidly customize the
speciﬁc genes being examined in an assay sim-
ply by adding or removing individual bead sets
from the assay’s mix. Our data demonstrate
that this approach can be used to create a high-
throughput screening assay to identify poten-
tial gene expression changes induced by a given
treatment, such as the one used in this study to
identify chemicals with estrogenic activity. The
multiplexing capability offers the opportunity
to screen large numbers of chemicals to deter-
mine their potential therapeutic and/or toxic
properties, in a cost- and animal-effective man-
ner using a customized set of genes. The com-
plete optimized protocol is described in
Table 4. The schematic representation of the
microsphere-based high-throughput gene
expression assay is shown in Figure 6.
The method presented in this article could
be used in a variety of applications related to
assaying for hybridization of a target polynu-
cleotide to an oligonucleotide probe and
ampliﬁcation of a signal generated thereby. It
can be used as a ﬁrst- or second-tier assay to
extract data of biomedical relevance for a wide
range of applications. For example, it can be
adapted to evaluate specific gene expression
changes used as “biomarkers” to identify
desired (therapeutic) versus undesired (toxic)
outcomes in the identification of different
pathogens present as potential contaminants of
food stuffs, drinking water or even in the air,
or in the determination of a pathological state
(e.g., see Bau et al. 2002; Rhodes et al. 2004;
Zhang et al. 2002).
Methods for the detection of speciﬁc tran-
scripts have advanced at a relative fast pace.
However, they have some drawbacks, including
A bead-based high-throughput gene expression assay
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Figure 5. Reproducibility of the assay, exemplified with the determination of the expression levels of
(A) Calb3 (up-regulated gene) and (B) Cyp17a1 (down-regulated gene) in ﬁve independent samples (bio-
logic replicas), in two independent experiments (Rep. 1 and Rep. 2) with the complete set of samples. Ten
micrograms of biotinylated cRNA from control vehicle-treated (control) or EE-exposed tissues (0.1, 1.0, or
10.0 µg/kg/day; low, medium, and high, respectively) was hybridized to microspheres in a ﬁve-plex format
(with the speciﬁc sets for Calb3, Cyp17a1, Ppib, Hsd11b2, and M13) under the optimized protocol as indi-
cated in “Materials and Methods.” Duplicate results and the means from ﬁve samples for each treatment
regimen are shown for Calb3 and Cyp17a1. The transcripts are identiﬁed in Table 1.
Table 2. Signal values (arbitrary fluorescent units) obtained from the microarray (Affymetrix) versus the
xMAP.
Gene Microarray xMAP
transcript Control 0.5 µg EE 1 µg EE 10 µg EE Control 0.5 µg EE 1 µg EE 10 µg EE
Star 2,558 2,626 370 (A) 296 (A) 1,169 1,366 384 397
Ehhadh 210 (A) 325 (A) 1,294 1,267 181 210 1,147 1,027
Scya11 293 (A) 855 (M) 4,542 10,419 843 1,296 5,039 10,210
C3 74 (A) 310 (A) 39,138 32,320 779 1,169 27,547 26,761
The average signal value of the indicated transcripts obtained from the uterus/ovaries from ﬁve females exposed to vehi-
cle control or the indicated doses of EE for 4 days (µg EE/kg/day) as indicated in Naciff et al. (2003). Transcripts for which
an absent (A) or marginal (M) call was determined (MAS 5.0, Affymetrix) in all the samples (n = 5) are noted even though
there is a signal value.high background noise, extended time and
labor requirements, lack of speciﬁcity, lack of
sensitivity, and a high entry and operation cost.
The method we have developed offers a cost-
efficient system that demonstrates low back-
ground noise, high speciﬁcity and sensitivity,
and after cRNA labeling can be completed in as
little as 4 hr. In the available literature, there are
some approaches to identify specific gene
expression changes; however, they have some
limitations overcome by the assay here
described. Particularly, Yang et al. (2001)
reported the use of microspheres linked to a
capture probe that has sequence complemen-
tary to a ﬁrst segment of a sequence of a single-
strand target nucleic acid. However, this
method is not as sensitive and can detect only
relatively abundant transcripts. On a different
approach, Fuja et al. (2004) described a four-
plex assay to determine the expression of four
genes using carboxyl–polystyrene particles of
four sizes. The primary limitation with this
approach is the limited number of different-
sized microspheres to expand the assay to
greater than four transcripts in a single reac-
tion. With a different approach Georgieva
et al. (2002) described a method based on
magnetic-activated cell separation followed by
a nested reverse-transcriptase–PCR to quantify
tyrosinase and MART-1 mRNA. The data
from these authors indicated a detection rate
comparable to that of other established total
RNA extraction methods. However, not all
the results were concordant, and the assay does
not seem to be very reliable. On a theoretical
basis Hug and Schuler (2003) proposed a
method to calculate the number of molecules
of a single mRNA species in a complex
Naciff et al.
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Table 3. Relative expression levela of selected genes determined by microarray compared with xMAP
technology.
Gene expression average fold change (n = 5)
Affymetrix xMAP run 1 xMAP run 2 xMAP run 2
Gene symbol microarrayb (high PMT) (high PMT) (low PMT)
VaACTIN 1.0 1.0 1.0 1.0
Ppib 1.0 1.1 1.1 1.1
Hsd11b2 4.0 3.3 4.2 3.9
Ctsb 2.6 3.8 3.2 3.6
Ckb 2.6 3.5 2.8 3.4
C3 295.0 144.0 36.2 100.2
Ehhadh 6.0 3.9 6.5 5.5
Scya11 35.5 14.4 12.7 14.6
Hspb1 2.1 2.2 2.0 2.1
Pgr 2.1 1.8 1.8 1.9
Calb3 10.5 46.5 10.7 35.2
Fn1 2.6 3.4 2.7 3.2
Cuzd1 12.9 38.3 16.7 38.2
Klf4 3.3 2.4 2.4 2.4
Star –8.7 –3.2 –3.1 –2.6
Igfbp3 –4.4 –2.5 –2.8 –2.6
Cyp17a1 –15.1 –6.1 –4.9 –4.8
Spp1 –3.5 –2.3 –2.3 –2.0
Cdk4 –1.6 –1.2 –1.2 –1.2
aThe relative expression level is represented by the ratio of high-dose EE-treated to control-treated samples. Run 1 was
done at Radix Biosolutions (read on a Luminex 100 ﬂow cytometer using SP1 software, version 1.7), and run 2 was done at
Procter & Gamble (read on the Bio-Rad Bio-Plex using the Bio-Plex Manager software, version 2.0). bThe Affymetrix
microarray data for the indicated genes, and many others, have been published (Naciff et al. 2003).
Table 4. Optimized protocol.
For duplicate wells
2.5 µg cRNA target per well
10 µL stock cRNA (0.5 µg/µL)
40 µL 1/2 × TMAC hybridization buffer containing 100 amol M13 oligo hybridization control spike
Microsphere mixture: 800 µL (enough for 20 samples)
2 µL each bead stock used in 20-plex (stock = 107 microspheres/mL)
760 µL 1/2 × TMAC hybridization buffer
Procedure
1. Add 25 µL diluted cRNA target.
2. Add 25 µL bead mix to each well according to step 1 above.
3. Incubate at 95°C for 2 min.
4. Transfer plate to thermo mixer, cover, and hybridize 3 hr up to overnight at 48°C while shaking at 500 rpm. 
5. Spin samples in centrifuge at 2,250 × g for 2 min; ﬂick and tap off solution.
6. Wash microspheres with 100 µL 1/2 × TMAC.
7. Spin samples in centrifuge at 2250 × g for 2 min; ﬂick and tap off solution.
8. Wash microspheres with 100 µL PBS–BSA.
9. Spin samples in centrifuge at 2,250 × g for 2 min; ﬂick and tap off solution.
10. Add 50 µL SAPE stain mix; shake at 500 rpm at 25°C for 15 min.
11. Spin samples in centrifuge at 2,250 × g for 2 min; ﬂick and tap off solution.
12. Wash microspheres with 100 µL PBS–BSA.
13. Spin samples in centrifuge at 2250 × g for 2 min; ﬂick and tap off solution.
14. Add 50 µL anti-streptavidin and goat IgG; shake at 500 rpm at 25°C for 60 min.
15. Spin samples in centrifuge at 2,250 × g for 2 min; ﬂick and tap off solution.
16. Wash microspheres with 100 µL PBS–BSA.
17. Spin samples in centrifuge at 2,250 × g for 2 min; ﬂick and tap off solution.
18. Add 50 µL SAPE; shake at 500 rpm at 25°C for 15 min.
19. Spin samples in centrifuge at 2,250 × g for 2 min; ﬂick and tap off solution.
20. Wash microspheres with 100 µL PBS–BSA.
21. Spin samples in centrifuge at 2,250 × g for 2 min; ﬂick and tap off solution.
22. Resuspend in 65 µL PBS–BSA and read on low- and then high-PMT settings of the instrument.
Probe-coupled beads Biotin-labeled cRNA
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SAPE
Biotin–anti-streptavidin
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Figure 6. Schematic representation of the micros-
phere-based high-throughput gene expression
assay. Fluorescent microspheres with covalently
bound oligonucleotides speciﬁc to the cRNA to be
quantified are incubated with cRNA and biotin (b)
labeled. Hybridized cRNA is revealed by SAPE
[phycoerythrin (PE)-conjugated streptavidin (SA)].
The signal is ampliﬁed by a second stain using the
biotinylated anti-streptavidin, followed by a third
staining step with SAPE.A bead-based high-throughput gene expression assay
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mRNA preparation by cloning tagged nucleic
acid molecules onto the surface of microbeads
and amplifying them, followed by their quan-
tification. However, to our knowledge this
method has not been implemented. For
another application of microsphere-based
assay, Spiro and Lowe (2002) developed a pro-
cedure for multiplexed quantiﬁcation of PCR
products using the bead method in a manner
that can lead to high-throughput testing, to
determine microorganisms from contaminated
groundwater. The major limitations of their
approach are the amount of starting material
they could quantify and the requirement for
PCR ampliﬁcation.
The assay we have developed overcomes
the various limitations found with other meth-
ods and is highly ﬂexible compared with cur-
rent methods. In addition the duration of the
assay hybridization step can vary from a mini-
mum of 1 hr up to 18 hr. Because hybridiza-
tion is between single-strand cRNA and
single-strand oligonucleotide capture probes,
increasing the hybridization time up to 18 hr
can double the sensitivity of the assay. The
enhancement of sensitivity described here per-
mits the amount of input material (cRNA) to
be as little as 1 µg in a complex mixture of
cRNAs or polynucleotides such as total RNA,
or mRNAs, according to the desired applica-
tion. The oligonucleotide(s) used to create the
assay may be preoptimized, as we have done,
or the multiplexing capability of the system
allows the optimized oligonucleotide to be
selected empirically. For example, one or more
oligonucleotides speciﬁc for the same gene may
be coupled to different microsphere sets, com-
bined, and subjected to a hybridization-based
assay to determine the best signal (speciﬁcity
and sensitivity) for the desired set of analytes.
Although in this study the ampliﬁed sig-
nal is detected using a ﬂow cytometer, other
means to detect the ampliﬁed signal are suit-
able and within the scope of the present
method. The Luminex-based analyzers use
standard 96-well plate formats, thereby pro-
viding this assay platform with higher sample
throughput capabilities than other standard
array formats. In addition, the use of the stan-
dard microtiter plate format makes the system
amenable to automation.
In summary, we have developed an assay to
quantify speciﬁc gene expression changes in a
complex background with high sensitivity and
specificity. We have made several improve-
ments on existing bead-based assays that pro-
vide results that highly correlate with standard
microarray technologies. We have achieved
detection levels down to 1 amol (10–18 mol),
detecting rare messages in complex cRNA sam-
ples, using as little as 2.5 µg. This assay offers
sensitivity greater than that achieved by
Affymetrix GeneChip microarrays with identi-
cal sample preparations. The assay can analyze
up to 100 analytes simultaneously (validated
with 20), is highly ﬂexible (add/subtract any
given analyte by adding or removing speciﬁc
microsphere sets), and offers signiﬁcant time
savings over QRT–PCR and it has high
throughput capabilities on a standard 96-well
format (scaleable to 384-well format).
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